What is GenScript ProBio?
GenScript ProBio operates within the dynamic Research & Development industry, a sector critical for scientific advancement and technological innovation. Headquartered in Piscataway, New Jersey, the company employs between 1000 to 4999 individuals and generates revenue in the range of $50 million to $100 million. Its focus on R&D positions it as a key player in developing cutting-edge solutions and technologies.
How much funding has GenScript ProBio raised?
GenScript ProBio has raised a total of $220M across 1 funding round:
Series C
$220M
Series C (2023): $220M with participation from Legend Capital
Key Investors in GenScript ProBio
Legend Capital
Legend Capital is a prominent private equity fund manager with a substantial track record, focusing on innovation and growth enterprises, particularly those with operations in or related to China. Their investment in GenScript ProBio suggests a strategic interest in the company's R&D capabilities and market potential.
What's next for GenScript ProBio?
With a substantial enterprise-level funding round and a recent strategic investment, GenScript ProBio is poised for accelerated growth and market penetration. The company is likely to leverage this capital to enhance its research capabilities, expand its operational footprint, and potentially pursue strategic partnerships or acquisitions. This financial backing signals strong investor confidence in GenScript ProBio's business model and its potential to drive significant advancements within the R&D landscape.
See full GenScript ProBio company page
